Signos secured $20 million to expand its glucose monitoring platform beyond diabetes and into weight loss. The approach combines Dexcom’s over-the-counter CGM offering with a software app that converts glucose trends into personalized diet and lifestyle recommendations. The funding is aimed at broadening the user base for CGM-guided behavior change and scaling the product’s weight-loss workflow. The update reflects continued investor interest in closed-loop-style digital health interventions that translate biometric data into clinical-adjacent guidance. Signos framed the move as expanding use cases for CGM while leveraging the reach of an OTC product and an added analytics layer tailored to lifestyle outcomes.